Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia

J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7. doi: 10.1097/QAI.0000000000000540.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use*
  • Atazanavir Sulfate
  • Female
  • Genetic Testing / methods*
  • Glucuronosyltransferase / genetics*
  • Humans
  • Hyperbilirubinemia / chemically induced*
  • Male
  • Middle Aged
  • Oligopeptides / adverse effects*
  • Oligopeptides / therapeutic use*
  • Pharmacogenetics / methods
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use*

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Pyridines
  • Atazanavir Sulfate
  • UGT1A1 enzyme
  • Glucuronosyltransferase